Related Experiment Video

Updated: Aug 1, 2026

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform
11:00

Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform

Published on: November 9, 2017

[Cytokine networks and their endogenous modulators in patients with congestive heart failure]

L Yang1, S Zhu, X Wang

  • 1Department of Cardiology, Kunming General Hospital, Chengdu Military Area, Kunming 650032, China.

Zhonghua Nei Ke Za Zhi
|January 5, 2002
PubMed

Insights

Cytokine network imbalance, with increased inflammatory markers like tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), is linked to severe congestive heart failure (CHF). This suggests a role in CHF development and progression.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Molecular Medicine

Context:

  • Congestive heart failure (CHF) is a complex syndrome with poorly understood pathophysiological mechanisms.
  • Cytokines, key mediators of inflammation and immune response, are increasingly recognized for their role in cardiovascular diseases.

Purpose:

  • To investigate the pathophysiological role of the cytokine network and its modulators in the development of congestive heart failure (CHF).
  • To quantify plasma levels of specific cytokines and their receptors in CHF patients compared to healthy controls.

Summary:

  • Patients with CHF exhibited elevated plasma levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and soluble TNF receptor I (sTNF-RI), alongside decreased transforming growth factor-beta (TGF-beta).
  • Ratios of TNF-alpha/sTNF-RI and TNF-alpha/TGF-beta were higher in CHF patients, particularly those with advanced heart failure (functional class IV).
  • TNF-alpha levels positively correlated with IL-6 and sTNF-RI, and negatively with TGF-beta, indicating a pro-inflammatory cytokine shift.

Impact:

  • The findings highlight a significant imbalance in the cytokine network in severe CHF, characterized by increased pro-inflammatory and inadequately regulated anti-inflammatory cytokines.
  • This dysregulation of the cytokine network may be a critical factor in the development and progression of congestive heart failure.
  • Understanding these cytokine interactions provides potential targets for novel therapeutic strategies in managing CHF.
Abstract

More Related Videos

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart11:53

Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

Published on: June 14, 2020

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...